Labia Majora Augmentation in 2026
- 1 day ago
- 10 min read
A clinical read for plastic surgeons, gynecologists, and aesthetic practitioners
Introduction
Aesthetic genital surgery has traditionally focused on labiaplasty, specifically reduction of the labia minora. Consequently, the published evidence, surgical training, and medico-legal discourse have largely centered on this procedure. By comparison, augmentation of the labia majora remains less extensively studied, despite increasing patient demand for correction of volume loss, tissue laxity, and age- or weight-related changes in vulvar contour. This disparity has left many clinicians without a well-defined, evidence-based framework for patient selection, procedural planning, and counseling.
The subject is particularly relevant to practitioners treating middle-aged patients and individuals following substantial weight loss, in whom deflation and structural changes of the labia majora may be prominent concerns. This review critically examines the available literature, identifies its principal methodological limitations, and evaluates developments that have emerged since publication of the field’s foundational systematic review.
Why the majora deflates — and why patients notice
The labia majora are, functionally, a facial analog. In youth they are full and smooth. With age, they lose subcutaneous fat and collagen, exactly as the face, hands, and body do. The result is deflation, wrinkling, and laxity — and, crucially, the "unveiling" of the labia minora and clitoral hood that were previously tucked behind full outer lips.
This matters clinically because the complaint that walks into your office as "my labia minora stick out" is often, on examination, a majora volume problem, not a minora excess problem. Reducing the minora in that patient can worsen the aesthetic and overcorrect a structure that was never the primary issue. Volume restoration of the majora is the more anatomically honest solution in a meaningful subset of these patients — the same logic that moved facial aesthetics away from pure excision toward volumization two decades ago.
The demand curve is real. The 2023 ISAPS global survey reported a roughly 20% year-on-year rise in procedures for vaginal rejuvenation and a ~15% rise in labiaplasty. Patients are asking. The question is whether we're answering from evidence or from anecdote.
The foundational evidence: the 2017 systematic review
The reference point for this field is Jabbour and colleagues' systematic review in Aesthetic Surgery Journal (2017), the first attempt to consolidate what was actually known. Searching Medline, Embase, and Cochrane, they found only nine studies worth including, covering 226 patients with a mean age of 43.6 years.
Only two were prospective. Everything else was retrospective or case-series level.
3 technique families emerged:
Autologous fat grafting — the most-studied approach (4 studies, 183 patients). Reported injected volumes ranged widely, from about 18 mL to 120 mL per session. The appeal is obvious: autologous tissue, no foreign material, concurrent contour improvement from the donor site. The trade-offs are equally familiar to anyone who grafts fat elsewhere — variable and unpredictable resorption, the need for a donor site, and dependence on operator processing technique.
Hyaluronic acid filler — 2 studies, with injected volumes of roughly 2 to 6 mL per session. Lower downtime, titratable, reversible with hyaluronidase, but temporary and — as discussed below — not without serious risk in this anatomy.
Surgical techniques — 3 studies, including approaches such as dermal fat grafts and direct excisional/advancement methods for laxity rather than pure volume loss.
The headline finding was reassuring on its face: across all techniques, no major or life-threatening complications were reported, and satisfaction rates were consistently high. But the review graded the overall body of evidence at Level 4, and the authors were explicit that randomized controlled trials were needed before any technique could be called a standard of care. High satisfaction in nine small, mostly retrospective studies is a signal — not proof.
That distinction is the whole point for a careful clinician. In 2017 you could tell a patient the procedure appeared safe and satisfying. You could not tell her it was validated.
What's changed since 2017 — the evidence is finally maturing
This is the part worth updating your mental model on, because the field has moved from "case series" toward "prospective data," and that changes the conversation you can honestly have with patients.
Prospective HA data now exists. The ESOLANE study (published 2025) was a prospective, multicenter, open-label investigation of a subcutaneous HA product (DESIRIAL PLUS) in 72 women treated for majora volume deficit, with structured outcomes tracked out to 52 weeks on a global aesthetic improvement scale. This is precisely the kind of durable, multi-timepoint prospective data the 2017 review said was missing.
Randomized data is coming. At least one industry-sponsored RCT (Genefill Contour vs comparator, NCT06333782) has been recruiting — a single-blind, randomized, multicenter design. Whatever the result, the arrival of randomized comparisons is the maturation step the original review called for.
Technique is being systematized. Rather than "inject where it looks deflated," authors have begun publishing anatomic frameworks — for example, a vulvar vector approach mapping specific injection points to achieve coaptation, volume, and skin-quality improvement reproducibly. Reproducibility is what turns a boutique procedure into a teachable one.
The filler conversation has broadened. Comparative work on calcium hydroxyapatite versus HA, and hybrid CaHA/HA protocols, now exists for majora atrophy — extending the toolkit beyond HA alone, with the biostimulatory rationale familiar from other body sites.
The safety point that separates competent practice from dangerous practice
Here is the caveat that deserves more emphasis than the "no major complications" headline gives it.
The absence of major complications in nine small studies does not mean this is a low-risk injection.
The vulva is highly vascular, and the catastrophic complication of filler in this region is intravascular injection leading to embolism. The literature includes a documented case of hyaluronic acid pulmonary embolism following an illegal cosmetic vaginal filler procedure. Facial filler experience has taught the field the mechanics of vascular occlusion in exhaustive detail; there is no anatomic reason to assume the genital region is exempt, and every reason — given the vascularity — to be more cautious, not less.
The practical implications are non-negotiable:
Fillers here are a physician procedure requiring genital anatomic expertise. This is not a delegate-to-anyone injection.
Aspirate, use cannulas where appropriate, inject slowly, in the correct subcutaneous plane, with small aliquots. The same discipline that prevents facial vascular events applies.
Have hyaluronidase and a vascular-occlusion protocol on hand whenever HA is used.
The rise of non-physician and unlicensed genital "rejuvenation" is where the real danger sits — the embolism case above came from an illegal procedure. Part of our job is being the safe, informed alternative.
Patient selection: who benefits, and who to avoid
Good outcomes here are decided at the consultation table more than in the procedure room. The strongest candidates share a clear profile.
Who benefits:
Volume loss and deflation of the majora from aging, menopause, significant or rapid weight change, or genetic predisposition — the analog of facial volume loss.
Patients whose minora appear to protrude specifically because the surrounding majora have lost fat. Restoring the outer envelope often resolves the complaint without touching the minora.
Patients with functional as well as aesthetic concerns — friction, irritation, or discomfort with clothing, activity, or intercourse from a deflated, lax outer lip.
Generally healthy patients with realistic expectations and no active dysmorphic fixation.
Who to defer or decline:
Active genital or local skin infection, pregnancy, or breastfeeding.
Known hypersensitivity to HA, or active autoimmune/connective tissue disease when considering filler (these were explicit exclusions in the prospective ESOLANE filler cohort).
Uncontrolled comorbidity, or a bleeding diathesis / anticoagulation that hasn't been risk-assessed.
Active smokers, specifically for fat grafting — smoking impairs graft take and wound healing; advise cessation roughly four weeks pre-procedure, as you would for any grafting.
Any suggestion of body dysmorphic disorder. Genital aesthetics attract a dysmorphic subgroup; screen for it, and don't operate your way into an unwinnable situation.
The single most useful selection question is mechanistic — is this a volume problem, a skin-excess problem, or both? Volume loss with good-quality skin favors fat grafting or filler. Genuine skin redundancy and laxity favors a surgical approach, because no injectable tightens skin. Mixed presentations often need staged or combined treatment, and saying so upfront protects both the result and the relationship.
Technique by modality
What follows is an orientation to how these procedures are described in the literature, not a substitute for hands-on training and credentialing.
Autologous fat grafting (lipomodeling). The most-studied approach. Harvest is typically from the abdomen or inner thigh/knee, processed per the surgeon's preferred method (the Coleman technique is the common reference point), and reinjected through fine cannulas in small aliquots. Many describe marking the target in the lithotomy position as a long oval running from the level of the outer introitus up toward the pubic prominence, a couple of centimeters above the upper clitoral hood. It can often be done under local anesthesia in an appropriately equipped office setting, without regional blocks, with same-day discharge. The defining counseling point is resorption — a meaningful and unpredictable fraction of graft (commonly cited around 30–50%) will not survive, so slight overcorrection and the possibility of a second session should be discussed before, not after.
Hyaluronic acid filler. The lower-downtime option, and the one with new prospective data behind it. The ESOLANE protocol is a useful reference technique: a blunt-tip cannula (18-gauge), entered anteriorly or posteriorly, with HA laid down in a slow linear retrograde (retrotracing) pass, up to roughly 2 mL per labium, in the subcutaneous/deep dermal plane. Use of a genital-formulated cross-linked HA, topical anesthesia with lidocaine often mixed into the product, and — non-negotiably — a blunt cannula, slow delivery, and avoidance of vascular compression. Results are immediate; longevity is generally in the 9–12 month range and maintenance is expected. The reversibility of HA with hyaluronidase is a genuine safety advantage over permanent materials, which have no place in this region.
Surgical and adjunctive techniques. For laxity and skin excess rather than pure volume loss, options include the dermal fat graft (which gives a durable, structural result) and excisional majora reduction when the tissue is frankly redundant or "baggy." Newer adjuncts such as PDO thread suspension for majora hypotrophy have small case series suggesting improvement in patient-reported genital self-image, though the evidence base is early and shouldn't be oversold.
Post-operative care
Aftercare differs meaningfully by modality, and clear written instructions prevent most avoidable problems.
After HA filler:
Expect transient swelling, mild redness, and occasional bruising; reassure that this is normal and self-limiting.
Avoid sexual intercourse for roughly 3–7 days.
Avoid heat — saunas, hot baths, thermal pools — for about a week.
Avoid prolonged direct pressure and sitting-intensive sports (cycling, horse riding) for one to two weeks.
The final aesthetic result settles at around two weeks; don't judge or top up before then.
Give explicit return precautions: escalating or disproportionate pain, dusky or blanched skin, or livedo-pattern discoloration are warnings of vascular compromise and warrant urgent review and hyaluronidase.
After fat grafting:
Swelling is more pronounced and can persist for four to six weeks; counsel that the visible result matures as swelling resolves (much of it visible by the first week, fully by six).
Protect graft take: avoid compression of the area — no tight underwear — and avoid intercourse for roughly three weeks, since pressure and shearing reduce graft survival.
Sexual activity and sports are generally reintroduced around the four-to-eight-week mark.
Gentle hygiene from day one: shower, don't scrub, and dab the area dry with a clean cloth.
Return to desk work is usually feasible within a few days.
Across all modalities:Â antiseptic preparation and sterile technique, clear infection and hematoma precautions, a named contact for concerns, and a scheduled review. For fat grafting, set expectations about a possible second session; for filler, about maintenance.
Practical takeaways for your practice
Diagnose the structure, not the complaint. Distinguish true minora excess from minora pseudo-protrusion caused by majora deflation. The second group is often better served by volume restoration than by reduction.
Match the tool to the pathology. Predominant volume loss with good skin → fat grafting or filler. Laxity and redundant skin → a surgical approach, since no filler tightens skin. Mixed presentations may need staged combinations.
Set expectations by mechanism. Fat grafting resorbs unpredictably and may need a second session; HA is temporary and will need maintenance; surgery is durable but carries incision, scar, and recovery considerations. Say so in consent.
Quote the evidence honestly. You can now cite prospective HA outcomes and emerging randomized data — a stronger position than 2017 — while being candid that long-term comparative effectiveness is still being established.
Treat the vascular risk as the headline, not the footnote. Your consent, your technique, and your emergency preparedness should reflect that embolism, though rare, is the complication that actually matters.
The bottom line
Labia majora augmentation has moved from a sparsely documented, Level-4 procedure toward a field with prospective data, emerging randomized trials, and the beginnings of technical standardization. For physicians, that shift is an opportunity and a responsibility: the demand is climbing regardless of whether we engage with it, and the patients seeking it will be treated by someone. Being the clinician who understands the anatomy, selects the right technique for the right pathology, and respects the vascular risk is both the safer and the more defensible position — for the patient and for you. Reference:
Jabbour S, Kechichian E, Hersant B, Levan P, El Hachem L, Noel W, Nasr M. Labia Majora Augmentation: A Systematic Review of the Literature. Aesthet Surg J. 2017;37(10):1157–1164. doi:10.1093/asj/sjx056. PMID: 28449124.
Hamori CA. Commentary on: Labia Majora Augmentation: A Systematic Review of the Literature. Aesthet Surg J. 2017;37(10):1165–1167. doi:10.1093/asj/sjx144.
Fasola E, Gazzola R. Labia Majora Augmentation with Hyaluronic Acid Filler: Technique and Results. Aesthet Surg J. 2016;36(10):1155–1163.
Salgado CJ, Tang JC, Desrosiers AE 3rd. Use of dermal fat graft for augmentation of the labia majora. J Plast Reconstr Aesthet Surg. 2012;65(2):267–270. PMID: 21803669.
ESOLANE study — Efficacy and Safety of Hyaluronic Acid Injection for Volume Restoration of the Labia Majora (DESIRIAL PLUS). Int Urogynecol J. 2025. doi:10.1007/s00192-025-06094-1.
Evaluation of the Safety and Efficacy of Hyaluronic Acid Injection (Genefill Contour) in Labia Majora Augmentation. ClinicalTrials.gov NCT06333782.
Amaral V de C. Systematization of labia majora augmentation with hyaluronic acid filler: the vulvar anatomical vector technique. Surg Cosmet Dermatol. 2024;16. doi:10.5935/scd1984-8773.2024160253.
Park HJ, Jung KH, Kim SY, Lee JH, Jeong JY, Kim JH. Hyaluronic acid pulmonary embolism: a critical consequence of an illegal cosmetic vaginal procedure. Thorax. 2010;65(4):360–361.
Boucher F, Fatton B, Deval B, et al. Evaluation of the efficacy and safety of hyaluronic acid injection for volume restoration of the labia majora: a prospective multicenter study (ESOLANE). Int Urogynecol J. 2025. (Technique: 18-G blunt cannula, linear retrograde, up to 2 mL/labium; autoimmune disease and HA hypersensitivity excluded.)
PDO thread suspension technique for labia majora hypotrophy (case series; Female Genital Self-Image Scale outcomes). PMC12481682.
ISAPS patient resource: Labia Majora Augmentation — technique, resorption, and recovery parameters. International Society of Aesthetic Plastic Surgery.
Learn the cutting-edge treatments in erectile dysfunction, male enhancement, vaginal tightening & more, taught by the expert faculties in Thailand
IFAAS Mini Fellowship (In-OR Observation)​
Non-Surgical Intimate Rejuvenation – Thai Edition
3-4 October, 2026 - Bangkok, Thailand  - [Register Now]
More Upcoming Global Events